Maridebart cafraglutide vs Semaglutide
GLP-1 agonism paired with GIP receptor antagonism — the opposite GIP direction to tirzepatide. A long-acting GLP-1 receptor agonist engineered for once-weekly dosing. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Maridebart cafraglutide MariTide | Semaglutide | |
|---|---|---|
| Also known as | — | Ozempic, Wegovy, Rybelsus |
| Type | Analog | Analog |
| Evidence | Investigational | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | GLP-1 agonist–GIP-antagonist peptide–antibody conjugate | GLP-1 receptor agonist (acylated peptide, 31 aa) |
| Receptor | GLP-1 receptor (agonist) + GIP receptor (antagonist) | GLP-1 receptor (GLP-1R) |
| Molecular weight | ≈150,000 Da | ~4,113.6 Da |
| Half-life | ||
| Based on | Glucagon-like peptide-1 | Glucagon-like peptide-1 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Maridebart cafraglutide and Semaglutide?
- Maridebart cafraglutide is an engineered analog based on Glucagon-like peptide-1; Semaglutide is an engineered analog based on Glucagon-like peptide-1. Maridebart cafraglutide signals at GLP-1 receptor (agonist) + GIP receptor (antagonist); Semaglutide signals at GLP-1 receptor (GLP-1R).
- How do the half-lives of MariTide and Semaglutide compare?
- The reported circulating half-life of Maridebart cafraglutide is ~21 days (monthly dosing); Semaglutide is ~7 days (~165 h). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Semaglutide vs Maridebart cafraglutide. Or open the interactive comparison tool to add more molecules.